glp 1 agonists and inflammation Anti-inflammatory role of glucagon-like peptide receptor its clinical implications Potential Use of GLP-1 and
Description
Young V, Eiser C, Johnson B, Brierley S, Epton T, Elliott J, et al
DPP-4 inhibitors: what may be the clinical differentiators
For answers, we turned to Terry Dubrow, MD, who has spent the last 18 months studying and testing retatrutide and other GLP-1 medications
Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary The GLP-1 agonists market in the 7MM is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan)
But Pfizer seems to have concluded that the toxicity question mark would damage its ability to compete in a relatively crowded space
